Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Ginkgo Bioworks Holdings, Inc. (DNA) Healthcare & Pipeline Overview

Ginkgo Bioworks Holdings, Inc. develops a cell programming platform, differentiating itself through the biological production of products for diverse sectors like pharmaceuticals, agriculture, and specialty chemicals. With a focus on synthetic biology, Ginkgo aims to revolutionize manufacturing processes across multiple industries, holding a unique position in the biotechnology landscape.

What Is the Investment Thesis for DNA?

Ginkgo Bioworks presents a compelling, albeit high-risk, investment thesis centered on its cell programming platform and its potential to disrupt multiple industries. The company's gross margin of 81.5% indicates strong pricing power and efficient production. However, a significant profit margin of -249.8% highlights the substantial investments required to scale its platform and commercialize its technologies. Key growth catalysts include expanding partnerships in the pharmaceutical and agricultural sectors and successfully developing new biological products. The company's beta of 1.57 suggests higher volatility compared to the market. Investors should closely monitor Ginkgo's ability to reduce its net losses and capitalize on its technological advantages to achieve sustainable profitability.

Based on FMP financials and quantitative analysis

DNA Key Highlights

Gross margin of 81.5% demonstrates strong pricing power and efficient production processes.

• Partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform expands technological capabilities.
• Serves diverse end markets including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals, reducing reliance on any single industry.
• Founded in 2008, Ginkgo Bioworks has established a significant presence in the synthetic biology sector.
• Market capitalization of $443M reflects its current valuation and growth potential.

Who Are DNA's Competitors?

DNA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are DNA's Key Strengths?

Proprietary cell programming platform.

• Diverse end market applications.
• Strategic partnerships.
• High gross margin.

What Are DNA's Weaknesses?

Significant net losses.

• High operating expenses.
• Reliance on partnerships for revenue generation.
• Complex regulatory environment.

What Could Drive DNA Stock Higher?

Expansion of partnerships in the pharmaceutical sector to develop novel therapeutics.

• Continued commercialization of biologically produced products across various industries.
• Development and advancement of the ImmTOR technology platform with Selecta Biosciences.
• Regulatory approvals for new biologically produced products in the food and agriculture sectors.

What Are the Key Risks for DNA?

Financial-distress signal — its Altman Z-Score of -8.97 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-57.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from other biotechnology companies with similar technologies.
• Technological obsolescence and the need for continuous innovation.
• Regulatory hurdles and the complex approval processes for biologically produced products.
• Economic downturn and reduced investment in biotechnology research and development.
• Failure to successfully commercialize new products and generate sustainable revenue.

What Are the Growth Opportunities for DNA?

• Expansion in the pharmaceutical sector represents a significant growth opportunity for Ginkgo Bioworks. By leveraging its cell programming platform to develop novel therapeutics and improve drug manufacturing processes, Ginkgo can tap into the multi-billion dollar pharmaceutical market. Collaborations with pharmaceutical companies to design and produce complex biologics could drive substantial revenue growth. Success in this area depends on navigating regulatory hurdles and demonstrating the efficacy and safety of its biologically produced therapeutics. This expansion is expected to unfold over the next 3-5 years.
• The agricultural sector offers another substantial growth avenue for Ginkgo Bioworks. With increasing demand for sustainable agricultural practices, Ginkgo's technology can be used to develop more efficient and environmentally friendly methods for crop production. This includes engineering microbes to enhance nutrient uptake, improve pest resistance, and reduce the need for chemical fertilizers. This growth is anticipated within the next 2-4 years.
• Penetration of the specialty chemicals market presents a viable growth opportunity. Ginkgo's cell programming platform can enable the biological production of specialty chemicals, offering a sustainable alternative to traditional petroleum-based manufacturing. This approach can reduce costs, improve efficiency, and minimize environmental impact. The specialty chemicals market is vast and diverse, encompassing a wide range of products used in various industries. Ginkgo's ability to tailor its platform to produce specific chemicals for different applications will be crucial for success. This expansion is expected to materialize over the next 3-5 years.
• Ginkgo Bioworks can capitalize on the growing demand for sustainable consumer products. By engineering microbes to produce bio-based materials and ingredients, Ginkgo can help consumer product companies reduce their reliance on fossil fuels and create more environmentally friendly products. This includes developing sustainable alternatives to plastics, fragrances, and other commonly used materials. The market for sustainable consumer products is expanding rapidly, driven by increasing consumer awareness and demand for eco-friendly options. This growth is anticipated within the next 2-3 years.
• Further development and commercialization of the ImmTOR technology platform, in partnership with Selecta Biosciences, represents a strategic growth opportunity. This platform aims to mitigate unwanted immune responses to biopharmaceuticals, potentially improving the efficacy and safety of these therapies. By expanding the applications of ImmTOR and securing additional partnerships, Ginkgo can generate significant revenue and establish itself as a leader in immune tolerance technology. The market for immune-modulating therapies is growing rapidly, driven by increasing demand for treatments for autoimmune diseases and other immune-related disorders. This growth is expected to unfold over the next 3-5 years.

What Are DNA's Competitive Advantages?

• Proprietary cell programming platform provides a technological advantage.
• Extensive library of engineered microbes creates a barrier to entry.
• Strategic partnerships with leading companies enhance market reach and credibility.
• Focus on diverse end markets reduces reliance on any single industry.

What Does DNA Do?

Founded in 2008 and headquartered in Boston, Massachusetts, Ginkgo Bioworks Holdings, Inc. is a biotechnology company specializing in cell programming. Ginkgo's core business revolves around its platform, which programs cells to biologically produce a wide array of products. These products span various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. The company's technology enables the creation of novel therapeutics, food ingredients, and chemicals derived from petroleum, offering a sustainable alternative to traditional manufacturing processes. Ginkgo's evolution has been marked by strategic partnerships, including its collaboration with Selecta Biosciences, Inc. to develop the ImmTOR technology platform. This partnership exemplifies Ginkgo's commitment to expanding its technological capabilities and market reach. By leveraging its cell programming platform, Ginkgo Bioworks aims to transform industries by replacing traditional manufacturing with biological processes, positioning itself as a key player in the future of biotechnology and sustainable production.

What Products and Services Does DNA Offer?

• Develop a platform for cell programming.
• Program cells to enable biological production of products.
• Serve the specialty chemicals market.
• Serve the agriculture market.
• Serve the food market.
• Serve the consumer products market.
• Serve the pharmaceuticals market.

How Does DNA Make Money?

• Ginkgo Bioworks generates revenue by providing its cell programming platform to customers across various industries.
• The company earns fees for designing and engineering microbes to produce specific products.
• Ginkgo also generates revenue through partnerships and collaborations with other companies, such as Selecta Biosciences.

What Industry Does DNA Operate In?

Ginkgo Bioworks operates within the rapidly evolving biotechnology industry, specifically in the synthetic biology segment. This industry is characterized by its potential to revolutionize manufacturing processes across various sectors, including pharmaceuticals, agriculture, and chemicals. The market is driven by increasing demand for sustainable and efficient production methods. Ginkgo's competitive landscape includes companies focusing on genetic engineering, metabolic engineering, and biomanufacturing. As the industry matures, strategic partnerships and technological advancements will be crucial for maintaining a competitive edge and capturing market share.

Who Are DNA's Key Customers?

• Specialty chemical companies seeking sustainable production methods.
• Agricultural companies looking to improve crop yields and reduce environmental impact.
• Food companies aiming to develop novel ingredients and improve food production processes.
• Consumer product companies seeking bio-based materials and ingredients.
• Pharmaceutical companies developing novel therapeutics.

Ginkgo Bioworks Holdings, Inc. (DNA) Valuation Context

Valued at $443M, DNA is classified as a small-cap stock. Analyst price targets span from $5.00 to $5.00, with a consensus of $5.00. At the current price of $6.78, that implies roughly 26% downside from the consensus target. Relative to its peer group, DNA's quantitative score of 12/100 is below the peer average of 78/100.

DNA Revenue & Earnings Trend

In Q2 FY2026, DNA generated $20.2M in top-line revenue, marking a sequential increase of 3.5%. The company recorded a net loss of $46.7M, with diluted EPS of $-0.75. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, DNA averaged $-1.26 in diluted EPS.

Company Profile

Ginkgo Bioworks Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Jason Kelly. DNA has traded publicly since 2021.

Return on equity for Ginkgo Bioworks Holdings, Inc. stands at -57.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -28.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -51.6%, the inverse of the P/E and a quick read on earnings relative to price.

Ginkgo Bioworks Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.97 places it in the distress zone, a signal of elevated financial risk.

Ginkgo Bioworks Holdings, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.4% above estimates on average.

Over the past six months, Ginkgo Bioworks Holdings, Inc. insiders filed 63 SEC Form 4 transactions — 31 sales and 32 purchases. On net that is roughly 606K shares acquired (about $3.6M) — insiders putting money in tends to read as conviction.

DNA Financials

DNA Latest News

DNA Analyst Consensus

DNA MoonshotScore

Latest Ginkgo Bioworks Holdings, Inc. Analysis

Related Investment Themes

What Investors Ask About Ginkgo Bioworks Holdings, Inc. (DNA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources